StockMacro
Menu

ARS Pharmaceuticals

$2.96 -64% in 6 monthsMarket cap $297.6M

SPRY on XNAS, Health Care, ARS Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly sales rose 16% but the stock fell 56% in a year while 19% of shares are shorted.

  • BadFree cash flow was -$183.1M over 12 months; cash $138.4M
  • BadTwelve-month revenue fell 14% to $122.1M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Industry
Pharmaceutical preparations (Health Care)
Employees
206
Website
ars-pharma.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 8 Mar 2027 (an estimate: a year ago it reported on 9 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $37.7M, net loss $35.6M.
Quarter to 31 Dec 2021: revenue –, net income -$23.5MQuarter to 31 Mar 2022: revenue $663K, net income -$24.6MQuarter to 31 Mar 2022: revenue $663K, net income -$24.6MQuarter to 30 Jun 2022: revenue $464K, net income -$19.4MQuarter to 30 Jun 2022: revenue $464K, net income -$19.4MQuarter to 30 Sep 2022: revenue $189K, net income -$17.9MQuarter to 30 Sep 2022: revenue $189K, net income -$17.9MQuarter to 31 Mar 2023: revenue $20K, net income -$15.0MQuarter to 31 Mar 2023: revenue $20K, net income -$15.0MQuarter to 30 Jun 2023: revenue $10K, net income -$17.4MQuarter to 30 Jun 2023: revenue $10K, net income -$17.4MQuarter to 30 Sep 2023: revenue $0, net income -$14.9MQuarter to 30 Sep 2023: revenue $0, net income -$14.9MQuarter to 31 Dec 2023: revenue –, net income -$7.2MQuarter to 31 Mar 2024: revenue $0, net income -$10.3MQuarter to 31 Mar 2024: revenue $0, net income -$10.3MQuarter to 30 Jun 2024: revenue $500K, net income -$12.5MQuarter to 30 Jun 2024: revenue $500K, net income -$12.5MQuarter to 30 Sep 2024: revenue $2.1M, net income -$19.1MQuarter to 30 Sep 2024: revenue $2.1M, net income -$19.1MQuarter to 31 Dec 2024: revenue $86.6M, net income $49.9MQuarter to 31 Dec 2024: revenue $86.6M, net income $49.9MQuarter to 31 Mar 2025: revenue $8.0M, net income -$33.9MQuarter to 31 Mar 2025: revenue $8.0M, net income -$33.9MQuarter to 30 Jun 2025: revenue $15.7M, net income -$44.9MQuarter to 30 Jun 2025: revenue $15.7M, net income -$44.9MQuarter to 30 Sep 2025: revenue $32.5M, net income -$51.2MQuarter to 30 Sep 2025: revenue $32.5M, net income -$51.2MQuarter to 31 Dec 2025: revenue $28.1M, net income -$41.3MQuarter to 31 Dec 2025: revenue $28.1M, net income -$41.3MQuarter to 31 Mar 2026: revenue $22.7M, net income -$60.6MQuarter to 31 Mar 2026: revenue $22.7M, net income -$60.6MQuarter to 30 Jun 2026: revenue $33.7M, net income -$62.3MQuarter to 30 Jun 2026: revenue $33.7M, net income -$62.3MQuarter to 30 Sep 2026: revenue $37.7M, net income -$35.6MQuarter to 30 Sep 2026: revenue $37.7M, net income -$35.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $86.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$37.7M-$35.6M
30 Jun 2026$33.7M-$62.3M
31 Mar 2026$22.7M-$60.6M
31 Dec 2025$28.1M-$41.3M
30 Sep 2025$32.5M-$51.2M
30 Jun 2025$15.7M-$44.9M
31 Mar 2025$8.0M-$33.9M
31 Dec 2024$86.6M$49.9M
30 Sep 2024$2.1M-$19.1M
30 Jun 2024$500K-$12.5M
31 Mar 2024$0-$10.3M
31 Dec 2023–-$7.2M
30 Sep 2023$0-$14.9M
30 Jun 2023$10K-$17.4M
31 Mar 2023$20K-$15.0M
30 Sep 2022$189K-$17.9M
30 Jun 2022$464K-$19.4M
31 Mar 2022$663K-$24.6M
31 Dec 2021–-$23.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $122.1M $142.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -14% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$199.9M -$80.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.02 -$0.82
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -161% -63.6% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -164% -56.1% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$183.1M -$86.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $138.4M $288.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $121.8M $96.2M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$16.5M (net cash) -$192.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.4 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.3 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ARS PharmaceuticalsSPRY (this company) $297.6Mloss2.4-14%-164%
EvommuneEVMN $291.1Mloss–––
Benitec BiopharmaBNTC $285.9Mloss–––
Greenwich LifeSciencesGLSI $282.6Mloss–––
Fulcrum TherapeuticsFULC $281.8Mloss–––
Relmada TherapeuticsRLMD $279.5Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-9.3%

185 13F filers vs 204

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

88.4M shares held by 13F filers (30 Sep 2026) of 100.5M outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

19%

19.0M shares sold short (30 Oct 2026) of 100.5M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.1

19.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.2%

19.8M shares sold short in the report before, 19.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

67%

67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

12

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+16%

$37.7M vs $32.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

17

17 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.9×

17 articles in the last 7 days; its usual week has 3.5.

Price $2.96 on 20 Nov 2026, -56% over 12 months (12-month range $2.65 to $13.06)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $284K in the last 12 months (the 12 months before: -$35.3M).
Revenue per quarter. Revenue $37.7M in the latest quarter, +16% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 185 13F filers reported holding it in the latest 13F quarter, +1.1% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Jul 20268-K and other filingsDirector or officer change
7 Jul 20268-K and other filingsDirector or officer change
13 May 20268-K and other filingsDirector or officer change
13 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 32.5M vs usual 1.3M (2025-09-30); 15.7x the same period a year earlier
14 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 15.7M vs usual 255K (2025-06-30); 31.4x the same period a year earlier
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 36 vs usual 22 (2025-03-31); 1.6x the same period a year earlier
1 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 86.6M vs usual 5,000 (2024-12-31)
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 46 vs usual 20.50 (2024-09-30); 2.3x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 11.9M vs usual 6.7M (2024-10-15); 2.1x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 11.1M vs usual 6.6M (2024-09-30); 1.9x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 11.6M vs usual 6.5M (2024-09-13); 2.0x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 11.0M vs usual 6.2M (2024-08-30); 2.0x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 12.1M vs usual 6.1M (2024-08-15); 2.1x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 9.9M vs usual 6.0M (2024-07-31); 1.6x the same period a year earlier
22 Feb 20238-K and other filingsA major agreement ended
9 Dec 20228-K and other filingsDirector or officer change
8 Nov 20228-K and other filingsDirector or officer change
8 Nov 20228-K and other filingsCompleted an acquisition or asset sale
30 Sep 20228-K and other filingsA major agreement ended
2 Sep 20228-K and other filingsDirector or officer change
21 Jul 20228-K and other filingsDirector or officer change
21 Jul 20228-K and other filingsRestructuring costs announced
21 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 May 20228-K and other filingsA major agreement ended
17 Mar 20228-K and other filingsDirector or officer change
17 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: $36K published
Month from 1 Dec 2022: $51K published
Month from 1 May 2023: -$781K published
Month from 1 Jun 2023: -$684K published
Month from 1 Jul 2023: -$647K published
Month from 1 Aug 2023: -$708K published
Month from 1 Sep 2023: $33.8M published
Month from 1 Oct 2023: $320K published
Month from 1 Feb 2024: -$897K published
Month from 1 Mar 2024: $11.4M published
Month from 1 Apr 2024: -$1.9M published
Month from 1 May 2024: -$1.8M published
Month from 1 Jun 2024: -$914K published
Month from 1 Jul 2024: -$2.1M published
Month from 1 Aug 2024: -$16.8M published
Month from 1 Sep 2024: -$2.6M published
Month from 1 Oct 2024: -$3.1M published
Month from 1 Nov 2024: -$14.6M published
Month from 1 Dec 2024: -$11.5M published
Month from 1 Jan 2025: -$555K published
Month from 1 Feb 2025: -$616K published
Month from 1 Mar 2025: -$700K published
Month from 1 Apr 2025: -$615K published
Month from 1 May 2025: -$3.9M published
Month from 1 Jun 2025: -$240K published
Month from 1 Jul 2025: -$13.9M published
Month from 1 Aug 2025: -$1.6M published
Month from 1 Nov 2025: -$1.7M published
Month from 1 Jun 2026: -$284K published
Revenue per quarter
Quarter ended 31 Mar 2022: $663K; public on 16 May 2023
Quarter ended 30 Jun 2022: $464K; public on 11 Aug 2023
Quarter ended 30 Sep 2022: $189K; public on 10 Nov 2023
Quarter ended 31 Mar 2023: $20K, -97% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $10K, -98% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $500K, +4900% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.1M; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $86.6M; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $8.0M; public on 15 May 2025
Quarter ended 30 Jun 2025: $15.7M, +3043% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $32.5M, +1472% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $28.1M, -68% on a year earlier; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $22.7M, +184% on a year earlier; public on 16 May 2026
Quarter ended 30 Jun 2026: $33.7M, +114% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $37.7M, +16% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $247K; public on 1 Apr 2022
Quarter ended 31 Dec 2021: $550K, +123% on a year earlier; public on 1 Apr 2022
Quarter ended 30 Sep 2022: $66K, -24% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Mar 2024: $83K; public on 10 May 2024
Quarter ended 30 Jun 2024: $38K; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $140K; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $302K; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $91K, +9.6% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $51K, +34% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $197K, +41% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 16 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 66; public on 14 Feb 2022
31 Mar 2022 report: 69; public on 16 May 2022
30 Jun 2022 report: 64; public on 15 Aug 2022
30 Sep 2022 report: 55; public on 14 Nov 2022
31 Dec 2022 report: 68; public on 14 Feb 2023
31 Mar 2023 report: 85; public on 15 May 2023
30 Jun 2023 report: 85; public on 14 Aug 2023
30 Sep 2023 report: 92; public on 14 Nov 2023
31 Dec 2023 report: 95; public on 14 Feb 2024
31 Mar 2024 report: 107; public on 15 May 2024
30 Jun 2024 report: 110; public on 14 Aug 2024
30 Sep 2024 report: 147; public on 14 Nov 2024
31 Dec 2024 report: 161; public on 14 Feb 2025
31 Mar 2025 report: 178; public on 15 May 2025
30 Jun 2025 report: 181; public on 14 Aug 2025
30 Sep 2025 report: 183; public on 14 Nov 2025
31 Dec 2025 report: 183; public on 17 Feb 2026
31 Mar 2026 report: 196; public on 15 May 2026
30 Jun 2026 report: 204; public on 14 Aug 2026
30 Sep 2026 report: 185; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is total debt at period end: short- and long-term borrowings at $121.8M (30 Sep 2026), higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $284K in the last 12 months (the 12 months before: -$35.3M).
  • Revenue per quarter: Revenue $37.7M in the latest quarter, +16% on a year earlier.
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 12 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Jun 2026Eric KarasChief Commercial OfficerSellplanned in advance (10b5-1); after exercising options25,000$10.00$250KForm 4
12 Jun 2026Alexander A FitzpatrickChief Legal OfficerSellplanned in advance (10b5-1)3,355$10.00$34KForm 4
14 Nov 2025Brian DorseyChief Operating OfficerSellafter exercising options21,828$8.71$190KForm 4
14 Nov 2025Justin ChakmaChief Business OfficerSellafter exercising options166,380$8.87$1.5MForm 4
22 Aug 2025Kathleen D. ScottChief Financial OfficerSellplanned in advance (10b5-1); after exercising options12,500$15.00$188KForm 4
22 Aug 2025Richard E LowenthalPRESIDENT AND CEOSellplanned in advance (10b5-1)50,000$14.49$724KForm 4
21 Aug 2025Sarina TanimotoCHIEF MEDICAL OFFICERSellplanned in advance (10b5-1)50,000$14.08$704KForm 4
3 Jul 2025Eric KarasChief Commercial OfficerSellplanned in advance (10b5-1); after exercising options15,000$16.99$255KForm 4

185 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 26 opened a position, 39 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Ra Capital Management, L.P.10.9M10.8%$46.8MNo change
Rubric Capital Management LP8.5M8.50%$36.8MNo change
Orbimed Advisors LLC8.3M8.24%$35.7MNo change
Deerfield Management Company, L.P.7.5M7.46%$32.3MNo change
BlackRock, Inc.5.6M5.55%$24.1M+271K+5.1%
Sr One Capital Management, LP4.0M3.99%$17.3MNo change
State Street Corp3.7M3.67%$15.9M-42K-1.1%
UBS Group AG3.7M3.65%$15.8M+1.7M+89%
Millennium Management LLC3.3M3.25%$14.1M+869K+36%
Tyro Capital Management LLC3.2M3.18%$13.8M-1.3M-28%

Company events

All 35 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
17 Jul 2026Director or officer change8-K
7 Jul 2026Director or officer change8-K
13 May 2026Director or officer change8-K
29 Sep 2025Signed a major agreementSame filing: took on new debt8-K
2 May 2025Signed a major agreement8-K
12 Nov 2024Signed a major agreement8-K
15 Oct 2024Signed a major agreement8-K
23 Sep 2024Signed a major agreement8-K

12 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 42%, Operations & administration 25%, Finance & accounting 17%, People & recruiting 8%.

PostedJobLocation
4 Nov 2026Specialty Sales Representative - Sacramento, CASales & business developmentUS - Remote
3 Nov 2026Senior Vice President, Human ResourcesPeople & recruitingSan Diego, California, United States
3 Nov 2026Specialty Sales Representative - Las Vegas & AlbuquerqueSales & business developmentUS - Remote
31 Oct 2026Manager / Senior Manager, Technical OperationsOperations & administrationSan Diego, California, United States
31 Oct 2026Director / Senior Director, Technical OperationsOperations & administrationSan Diego, California, United States
30 Oct 2026Senior Director, Trade Strategy, Distribution & Strategic AccountsSales & business developmentUS - Remote
23 Oct 2026Associate Director / Director, Quality AssuranceFinance & accountingSan Diego, California, United States
22 Oct 2026Manager / Senior Manager, Quality AssuranceFinance & accountingSan Diego, California, United States

The 5 newest of 164 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 May 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials

ARS Pharmaceuticals (SPRY): reported revenue of $86.6M for the quarter ended 31 Dec 2024, against none in the same quarter last year, while it saw 36 13F filers open a new position in the quarter ended 31 Mar 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 1 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
2022-12-31: $02023-03-31: $20K2023-06-30: $10K2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M
The quarter ended 31 Dec 2024 against the 8 quarters before it. this quarterearliernormal: $5K
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 1 May 2025

ARS Pharmaceuticals reported revenue of $86.6M for the quarter ended 31 Dec 2024, against none in the same quarter last year.

This period
$86.6M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$5K
Typical spread (median absolute deviation)
$5K
How far from its usual level
+86.6
Same quarter last year
$0
History used
1,006 days
2022-12-31: $02023-03-31: $20K2023-06-30: $10K2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M
the quarter ended 31 Dec 20248 earlier quartersnormal: $5K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

ARS Pharmaceuticals saw 36 13F filers open a new position in the quarter ended 31 Mar 2025, 1.6× the same quarter last year.

This period
36 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
22
Typical spread (median absolute deviation)
2
How far from its usual level
+4.7
Same quarter last year
23
History used
1,551 days
2023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 462024-12-31: 242025-03-31: 36
the quarter ended 31 Mar 20258 earlier quartersnormal: 22

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

19 Nov 2024confirmed

Confirmed across sources Institutional holdings and Short interest and volume

ARS Pharmaceuticals (SPRY): had 11.9M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year, while it saw 46 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 25 Oct 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M2024-09-30: 11.1M2024-10-15: 11.9M
The 15 Oct 2024 report against the 24 reports before it. this reportearliernormal: 6.7M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 25 Oct 2024

ARS Pharmaceuticals had 11.9M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.

This period
11.9M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
947K
How far from its usual level
+3.7
Same report last year
5.7M
History used
700 days
2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M2024-09-30: 11.1M2024-10-15: 11.9M
the 15 Oct 2024 report24 earlier reportsnormal: 6.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

ARS Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.

This period
46 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.5
Same quarter last year
20
History used
1,369 days
2022-09-30: 82022-12-31: 222023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 46
the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Jul 2026Filings record

    Director or officer change

  2. 7 Jul 2026Filings record

    Director or officer change

  3. 13 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 13 May 2026Filings record

    Director or officer change

  5. 11 Nov 2025Financials change

    reported revenue of $32.5M for the quarter ended 30 Sep 2025, 16× the same quarter last year.

    Same quarter last year: $2.1M; its normal quarter is $1.3M.

    See the evidence
    This period
    $32.5M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $1.3M
    Typical spread (median absolute deviation)
    $1.3M
    How far from its usual level
    +16.4
    Same quarter last year
    $2.1M
    History used
    1,279 days
    2023-06-30: $10K2023-09-30: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M2025-03-31: $8.0M2025-06-30: $15.7M2025-09-30: $32.5M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $1.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 14 Aug 2025Financials change

    reported revenue of $15.7M for the quarter ended 30 Jun 2025, 31× the same quarter last year.

    Same quarter last year: $500K; its normal quarter is $255K.

    See the evidence
    This period
    $15.7M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $255K
    Typical spread (median absolute deviation)
    $255K
    How far from its usual level
    +15.5
    Same quarter last year
    $500K
    History used
    1,187 days
    2023-06-30: $10K2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M2025-03-31: $8.0M2025-06-30: $15.7M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $255K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 15 May 2025several at once

    reported revenue of $86.6M for the quarter ended 31 Dec 2024, against none in the same quarter last year, while it saw 36 13F filers open a new position in the quarter ended 31 Mar 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 1 May 2025

    ARS Pharmaceuticals reported revenue of $86.6M for the quarter ended 31 Dec 2024, against none in the same quarter last year.

    This period
    $86.6M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $5K
    Typical spread (median absolute deviation)
    $5K
    How far from its usual level
    +86.6
    Same quarter last year
    $0
    History used
    1,006 days
    2022-12-31: $02023-03-31: $20K2023-06-30: $10K2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $5K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 15 May 2025

    ARS Pharmaceuticals saw 36 13F filers open a new position in the quarter ended 31 Mar 2025, 1.6× the same quarter last year.

    This period
    36 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    22
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.7
    Same quarter last year
    23
    History used
    1,551 days
    2023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 462024-12-31: 242025-03-31: 36
    the quarter ended 31 Mar 20258 earlier quartersnormal: 22

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  8. 15 May 2025Institutional holdings change

    saw 36 13F filers open a new position in the quarter ended 31 Mar 2025, 1.6× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 22.

    See the evidence
    This period
    36 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    22
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.7
    Same quarter last year
    23
    History used
    1,551 days
    2023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 462024-12-31: 242025-03-31: 36
    the quarter ended 31 Mar 20258 earlier quartersnormal: 22

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 1 May 2025Financials change

    reported revenue of $86.6M for the quarter ended 31 Dec 2024, against none in the same quarter last year.

    See the evidence
    This period
    $86.6M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $5K
    Typical spread (median absolute deviation)
    $5K
    How far from its usual level
    +86.6
    Same quarter last year
    $0
    History used
    1,006 days
    2022-12-31: $02023-03-31: $20K2023-06-30: $10K2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $500K2024-09-30: $2.1M2024-12-31: $86.6M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $5K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  10. 19 Nov 2024several at once

    had 11.9M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year, while it saw 46 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 25 Oct 2024

    ARS Pharmaceuticals had 11.9M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.

    This period
    11.9M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    6.7M
    Typical spread (median absolute deviation)
    947K
    How far from its usual level
    +3.7
    Same report last year
    5.7M
    History used
    700 days
    2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M2024-09-30: 11.1M2024-10-15: 11.9M
    the 15 Oct 2024 report24 earlier reportsnormal: 6.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

    ARS Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.

    This period
    46 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    20.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.5
    Same quarter last year
    20
    History used
    1,369 days
    2022-09-30: 82022-12-31: 222023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 46
    the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  11. 14 Nov 2024Institutional holdings change

    saw 46 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.

    Same quarter last year: 20; its normal quarter is 20.5.

    See the evidence
    This period
    46 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    20.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.5
    Same quarter last year
    20
    History used
    1,369 days
    2022-09-30: 82022-12-31: 222023-03-31: 212023-06-30: 282023-09-30: 202023-12-31: 152024-03-31: 232024-06-30: 202024-09-30: 46
    the quarter ended 30 Sep 20248 earlier quartersnormal: 20.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 25 Oct 2024Short interest and volume change

    had 11.9M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.

    Same report last year: 5.7M; its normal report is 6.7M.

    See the evidence
    This period
    11.9M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    6.7M
    Typical spread (median absolute deviation)
    947K
    How far from its usual level
    +3.7
    Same report last year
    5.7M
    History used
    700 days
    2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M2024-09-30: 11.1M2024-10-15: 11.9M
    the 15 Oct 2024 report24 earlier reportsnormal: 6.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 Oct 2024Short interest and volume change

    had 11.1M shares sold short in the 30 Sep 2024 report, 1.9× the same report last year.

    Same report last year: 5.9M; its normal report is 6.6M.

    See the evidence
    This period
    11.1M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    6.6M
    Typical spread (median absolute deviation)
    737K
    How far from its usual level
    +4.1
    Same report last year
    5.9M
    History used
    685 days
    2023-09-29: 5.9M2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M2024-09-30: 11.1M
    the 30 Sep 2024 report24 earlier reportsnormal: 6.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 25 Sep 2024Short interest and volume change

    had 11.6M shares sold short in the 13 Sep 2024 report, 2.0× the same report last year.

    Same report last year: 5.8M; its normal report is 6.5M.

    See the evidence
    This period
    11.6M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    6.5M
    Typical spread (median absolute deviation)
    588K
    How far from its usual level
    +5.9
    Same report last year
    5.8M
    History used
    668 days
    2023-09-15: 5.8M2023-09-29: 5.9M2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M2024-09-13: 11.6M
    the 13 Sep 2024 report24 earlier reportsnormal: 6.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 12 Sep 2024Short interest and volume change

    had 11.0M shares sold short in the 30 Aug 2024 report, 2.0× the same report last year.

    Same report last year: 5.4M; its normal report is 6.2M.

    See the evidence
    This period
    11.0M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    6.2M
    Typical spread (median absolute deviation)
    642K
    How far from its usual level
    +5.0
    Same report last year
    5.4M
    History used
    654 days
    2023-08-31: 5.4M2023-09-15: 5.8M2023-09-29: 5.9M2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M2024-08-30: 11.0M
    the 30 Aug 2024 report24 earlier reportsnormal: 6.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 27 Aug 2024Short interest and volume change

    had 12.1M shares sold short in the 15 Aug 2024 report, 2.1× the same report last year.

    Same report last year: 5.8M; its normal report is 6.1M.

    See the evidence
    This period
    12.1M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    726K
    How far from its usual level
    +5.6
    Same report last year
    5.8M
    History used
    639 days
    2023-08-15: 5.8M2023-08-31: 5.4M2023-09-15: 5.8M2023-09-29: 5.9M2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M2024-08-15: 12.1M
    the 15 Aug 2024 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 Aug 2024Short interest and volume change

    had 9.9M shares sold short in the 31 Jul 2024 report, 1.6× the same report last year.

    Same report last year: 6.1M; its normal report is 6.0M.

    See the evidence
    This period
    9.9M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    6.0M
    Typical spread (median absolute deviation)
    655K
    How far from its usual level
    +4.0
    Same report last year
    6.1M
    History used
    624 days
    2023-07-31: 6.1M2023-08-15: 5.8M2023-08-31: 5.4M2023-09-15: 5.8M2023-09-29: 5.9M2023-10-13: 5.7M2023-10-31: 6.6M2023-11-15: 5.9M2023-11-30: 6.0M2023-12-15: 6.7M2023-12-29: 7.0M2024-01-12: 6.9M2024-01-31: 4.9M2024-02-15: 4.9M2024-02-29: 4.6M2024-03-15: 4.3M2024-03-28: 5.5M2024-04-15: 6.1M2024-04-30: 6.4M2024-05-15: 6.9M2024-05-31: 6.8M2024-06-14: 6.8M2024-06-28: 6.9M2024-07-15: 8.7M2024-07-31: 9.9M
    the 31 Jul 2024 report24 earlier reportsnormal: 6.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 28 Mar 2024Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 1,401,299 shares of SPRY ($13.3M) (dated 27 Mar 2024)

  19. 3 Oct 2023Insiders record

    Fitzpatrick Alexander A (Chief Legal Officer) bought 86,258 shares of SPRY ($319,655) (dated 2 Oct 2023)

  20. 26 Sep 2023Insiders record

    RA Capital Healthcare Fund LP (director) and 4 other(s) bought 2,700,000 shares of SPRY ($8.2M) (dated 25 Sep 2023)

  21. 1 Sep 2023Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 3,750,000 shares of SPRY ($23.2M) (dated 31 Aug 2023)

  22. 1 Sep 2023Insiders record

    OrbiMed Capital GP VI LLC (director) and 2 other(s) bought 500,000 shares of SPRY [same transaction as an earlier filing] (dated 31 Aug 2023)

  23. 1 Sep 2023Insiders record

    Thompson Peter A. (director) bought 500,000 shares of SPRY ($3.1M) (dated 31 Aug 2023)

  24. 22 Feb 2023Filings record

    A major agreement ended

  25. 9 Dec 2022Filings record

    Director or officer change

  26. 2 Dec 2022Insiders record

    Scott Kathleen D. (Chief Financial Officer) bought 8,250 shares of SPRY ($51,480) (dated 1 Dec 2022)

  27. 8 Nov 2022Filings record

    Director or officer change

  28. 8 Nov 2022Filings record

    Completed an acquisition or asset sale

  29. 30 Sep 2022Filings record

    A major agreement ended

  30. 2 Sep 2022Filings record

    Director or officer change

  31. 21 Jul 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 21 Jul 2022Filings record

    Director or officer change

  33. 21 Jul 2022Filings record

    Restructuring costs announced

  34. 6 May 2022Filings record

    A major agreement ended

  35. 19 Mar 2022Insiders record

    ROOT JONATHAN D (director) bought 2,364 shares of SBTX ($36,048) (dated 18 Mar 2022)

  36. 17 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 17 Mar 2022Filings record

    Director or officer change

  38. 25 Feb 2022Insiders record

    Hawkinson Russ (Sr. Vice President of Finance) bought 200 shares of SBTX ($4,200) [amended] (dated 24 Feb 2022)

  39. 15 Mar 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 15 Mar 2021Filings record

    Director or officer change

Showing the newest 40 of 60 entries; narrow the window or the kind of data to see older ones.

Not listed: 158 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001671858
Ticker
SPRY
Domain
ars-pharma.com
Hq location
CA|SAN DIEGO|92130 (1 unverified)
Name
ARS Pharmaceuticals, Inc., Silverback Therapeutics, Inc.
Wikidata
Q87556967
  • SEC Form 13F institutional holdings1 record, 216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)94 records12 Apr 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)387 data points31 Dec 2019 to 3 Nov 2026
  • SEC Form 4 insider transactions105 records, 228 data points8 Dec 2020 to 12 Jun 2026
  • FINRA short interest (twice monthly)288 data points15 Nov 2022 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2022 data points9 Nov 2022 to 20 Nov 2026